author-photo

Sanjay Popat

The Royal Marsden NHS Foundation Trust
National Institutes of Health
Institute of Cancer Research

479

Papers

12846

Citations

Citation Trend

Filter By

Papers (336) Sort By

Journal Conference Others

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications.

2021 Frontiers of Medicine in China
Show All
- Source
- Cite
- Save
Citations (0)
Treatment dose-delay due to an exercise induced creatinine kinase level elevation/raise in a man with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) – a case report

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
HER-3 Expression and MEK Activation in Non-small Cell Lung Cancer

2021
Show All
- Source
- Cite
- Save
Citations (0)
1212P Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Brain metastases in solid tumours: new guidelines for a new era.

2021 Annals of Oncology
- Sanjay Popat
- Lyndsey Welsh
Show All
- Source
- Cite
- Save
Citations (0)
FP09.02 Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Early response to chemotherapy in malignant pleural mesothelioma assessed using diffusion-weighted MRI: Initial observations

2021
Show All
- Source
- Cite
- Save
Citations (0)
Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)